BACKGROUND: Antidepressant drugs are used as first-line treatment in depression, but response has been shown to be highly heterogeneous, with drugs often failing to have the desired therapeutic effect. We report on an integrative analysis from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study using gene expression from mice to inform prioritization in a human pharmacogenetic study. METHODS: The same two antidepressants were used in mice and humans: escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). The animal study used four inbred strains of mice (129S1/SvlmJ, C57LB/6J, DBA/2J, and FVB/NJ). Hippocampus mRNA levels were measured in 144 animals using the Affymetrix MOE 430 v2 chip. RESULTS: Based on gene-expression analysis of strain-by-drug interactions, 17 genes differentially expressed with nortriptyline or escitalopram versus saline were prioritized in the human pharmacogenetic analysis. Single nucleotide polymorphisms tagging common sequence variation in human orthologs of these genes were tested for association with response to antidepressants in 706 participants of the GENDEP human pharmacogenetic study, treated withescitalopram or nortriptyline for 12 weeks, with available high-quality Illumina 610 quad array genotyping. Several polymorphisms in the protein phosphatase 1A gene (PPM1A) remained significantly associated with response to nortriptyline in humans after correction for multiple comparisons within the gene. PPM1A encodes a phosphatase involved in mitogen-activated protein kinase signaling and cell stress response. CONCLUSIONS: Convergent evidence from mice and humans suggests a role of the PPM1A in response to noradrenergic but not serotonergic antidepressants.
RCT Entities:
BACKGROUND: Antidepressant drugs are used as first-line treatment in depression, but response has been shown to be highly heterogeneous, with drugs often failing to have the desired therapeutic effect. We report on an integrative analysis from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study using gene expression from mice to inform prioritization in a human pharmacogenetic study. METHODS: The same two antidepressants were used in mice and humans: escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor). The animal study used four inbred strains of mice (129S1/SvlmJ, C57LB/6J, DBA/2J, and FVB/NJ). Hippocampus mRNA levels were measured in 144 animals using the Affymetrix MOE 430 v2 chip. RESULTS: Based on gene-expression analysis of strain-by-drug interactions, 17 genes differentially expressed with nortriptyline or escitalopram versus saline were prioritized in the human pharmacogenetic analysis. Single nucleotide polymorphisms tagging common sequence variation in human orthologs of these genes were tested for association with response to antidepressants in 706 participants of the GENDEP human pharmacogenetic study, treated with escitalopram or nortriptyline for 12 weeks, with available high-quality Illumina 610 quad array genotyping. Several polymorphisms in the protein phosphatase 1A gene (PPM1A) remained significantly associated with response to nortriptyline in humans after correction for multiple comparisons within the gene. PPM1A encodes a phosphatase involved in mitogen-activated protein kinase signaling and cell stress response. CONCLUSIONS: Convergent evidence from mice and humans suggests a role of the PPM1A in response to noradrenergic but not serotonergic antidepressants.
Authors: Melloni N Cook; Jessica A Baker; Scott A Heldt; Robert W Williams; Kristin M Hamre; Lu Lu Journal: Physiol Genomics Date: 2015-05-19 Impact factor: 3.107
Authors: Karim Malki; Maria Grazia Tosto; Héctor Mouriño-Talín; Sabela Rodríguez-Lorenzo; Oliver Pain; Irfan Jumhaboy; Tina Liu; Panos Parpas; Stuart Newman; Artem Malykh; Lucia Carboni; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk; Kevin Bryson; Mark Herbster Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-10-01 Impact factor: 3.568
Authors: Caroline Durrant; Morris A Swertz; Rudi Alberts; Danny Arends; Steffen Möller; Richard Mott; Pjotr Prins; K Joeri van der Velde; Ritsert C Jansen; Klaus Schughart Journal: Brief Bioinform Date: 2011-07-08 Impact factor: 11.622
Authors: Karim Malki; Yann S Mineur; Maria Grazia Tosto; James Campbell; Priya Karia; Irfan Jumabhoy; Frans Sluyter; Wim E Crusio; Leonard C Schalkwyk Journal: BMC Genomics Date: 2015-04-03 Impact factor: 3.969
Authors: K Ganea; A Menke; M V Schmidt; S Lucae; G Rammes; C Liebl; D Harbich; V Sterlemann; C Storch; M Uhr; F Holsboer; E B Binder; I Sillaber; M B Müller Journal: Transl Psychiatry Date: 2012-10-23 Impact factor: 6.222
Authors: Katherine E Tansey; Michel Guipponi; Nader Perroud; Guido Bondolfi; Enrico Domenici; David Evans; Stephanie K Hall; Joanna Hauser; Neven Henigsberg; Xiaolan Hu; Borut Jerman; Wolfgang Maier; Ole Mors; Michael O'Donovan; Tim J Peters; Anna Placentino; Marcella Rietschel; Daniel Souery; Katherine J Aitchison; Ian Craig; Anne Farmer; Jens R Wendland; Alain Malafosse; Peter Holmans; Glyn Lewis; Cathryn M Lewis; Tine Bryan Stensbøl; Shitij Kapur; Peter McGuffin; Rudolf Uher Journal: PLoS Med Date: 2012-10-16 Impact factor: 11.069